EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #15024_C
通过免疫密度分离法分选未被标记的B细胞
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
总览
RosetteSep™人B细胞富集抗体混合物设计通过负选从全血分离B细胞。四聚体抗体复合物可识别非B细胞和红细胞（RBC）上的糖蛋白A，从而靶向去除非目的细胞。使用浮力密度梯度离心液（如RosetteSep™ DM-L（产品号 #15705）或Lymphoprep™（产品号 #18060）离心后时，非目的细胞会与红细胞一起沉淀。纯化的B细胞为血浆和密度梯度离心液的交界界面中高度富集的细胞。
分类
细胞分选试剂盒
细胞类型
B 细胞
种属
人
样本来源
白膜层、全血
分选方法
负选
应用
细胞分选
品牌
RosetteSep
研究领域
免疫
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (9)
常见问题 (9)
文献 (43)
Dual membrane receptor degradation via folate receptor targeting chimera
Nature Communications 2025 Oct
Abstract
Cancer drug resistance poses a significant challenge in oncology, often driven by intricate cross-talk among membrane-bound receptors that compromise mono-targeted therapies. We develop a dual membrane receptor degradation strategy leveraging Folate Receptor α (FRα) to address this issue. Folate Receptor α Targeting Chimeras-dual (FolTAC-dual) are engineered degraders designed to selectively and simultaneously degrade distinct receptor pairs: (1) EGFR/HER2 and (2) PD-L1/VISTA. Through modular optimization of modality configurations and geometries, we identify the “string” format as the most effective construct. Mechanistic studies demonstrate an ~85% increase in EGFR-binding affinity compared to the conventional knob-into-hole design, likely contributing to the improved efficiency of dual-target degradation. Proof-of-concept studies reveal that EGFR and HER2 FolTAC-dual effectively counteracts resistance in Trastuzumab/Lapatinib-resistant HER2-positive breast cancer models, while PD-L1 and VISTA FolTAC-dual rejuvenates immune responses in PD-L1 antibody-resistant syngeneic mouse models. These findings establish FolTAC-dual as a promising dual-degradation platform for clinical translation. Subject terms: Cancer immunotherapy, Targeted therapies, Protein design, Drug discovery and development
A spatiotemporal map of co-receptor signaling networks underlying B cell activation
Cell reports 2024 Jun
Abstract
The B cell receptor (BCR) signals together with a multi-component co-receptor complex to initiate B cell activation in response to antigen binding. Here, we take advantage of peroxidase-catalyzed proximity labeling combined with quantitative mass spectrometry to track co-receptor signaling dynamics in Raji cells from 10 s to 2 h after BCR stimulation. This approach enables tracking of 2,814 proximity-labeled proteins and 1,394 phosphosites and provides an unbiased and quantitative molecular map of proteins recruited to the vicinity of CD19, the signaling subunit of the co-receptor complex. We detail the recruitment kinetics of signaling effectors to CD19 and identify previously uncharacterized mediators of B cell activation. We show that the glutamate transporter SLC1A1 is responsible for mediating rapid metabolic reprogramming and for maintaining redox homeostasis during B cell activation. This study provides a comprehensive map of BCR signaling and a rich resource for uncovering the complex signaling networks that regulate activation.
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells
Gene Therapy 2024 Apr
Abstract
Allogeneic cell therapies, such as those involving macrophages or Natural Killer (NK) cells, are of increasing interest for cancer immunotherapy. However, the current techniques for genetically modifying these cell types using lenti- or gamma-retroviral vectors present challenges, such as required cell pre-activation and inefficiency in transduction, which hinder the assessment of preclinical efficacy and clinical translation. In our study, we describe a novel lentiviral pseudotype based on the Koala Retrovirus (KoRV) envelope protein, which we identified based on homology to existing pseudotypes used in cell therapy. Unlike other pseudotyped viral vectors, this KoRV-based envelope demonstrates remarkable efficiency in transducing freshly isolated primary human NK cells directly from blood, as well as freshly obtained monocytes, which were differentiated to M1 macrophages as well as B cells from multiple donors, achieving up to 80% reporter gene expression within three days post-transduction. Importantly, KoRV-based transduction does not compromise the expression of crucial immune cell receptors, nor does it impair immune cell functionality, including NK cell viability, proliferation, cytotoxicity as well as phagocytosis of differentiated macrophages. Preserving immune cell functionality is pivotal for the success of cell-based therapeutics in treating various malignancies. By achieving high transduction rates of freshly isolated immune cells before expansion, our approach enables a streamlined and cost-effective automated production of off-the-shelf cell therapeutics, requiring fewer viral particles and less manufacturing steps. This breakthrough holds the potential to significantly reduce the time and resources required for producing e.g. NK cell therapeutics, expediting their availability to patients in need. Subject terms: Genetic transduction, Tumour immunology, Immunotherapy, Genetic vectors, Innate immune cells
更多信息
| 物种 | 人类 |
|---|---|
| 样本来源 | 全血, 白膜层 |
| Selection Method | Negative |
相关产品
-
EasySep™ Direct人B细胞分选试剂盒<p>直接从全血中分离未标记人 B 细胞的免疫磁珠负选分离</p>
-
SepMate™-50 (IVD)用于体外诊断(IVD)应用的密度梯度离心管
标记抗体
-
抗人CD19抗体，clone HIB19抗人、黑猩猩CD19的小鼠Monoclonal IgG1抗体
-
抗人CD20抗体，clone 2H7小鼠Monoclonal IgG2b抗体，抗人、恒河猴、食蟹猴CD20
沪公网安备31010102008431号
在线联系